EUVIMEDEUVIMED entdecken
Kommentar

The narrow path to CD8+ T cell recognition of mutant p53

Evan W Newell

Immunity · 2026

DOI: 10.1016/j.immuni.2026.09.020 ↗

Kurz gefasst

Kommentar in der Zeitschrift Immunity, 2026. Verfasst von Evan W Newell. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: enewell@fredhutch.org. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit nennt 10 Literaturangaben. Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Shared cancer driver mutations offer attractive targets for cancer immunotherapy, but their expression does not necessarily put them within the reach of a T cell response. In this issue of Immunity, Haratani et al. identify distinct barriers to the processing, presentation, and recognition of neoantigens generated from mutant p53 that help explain this gap.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53CD8-Positive T-LymphocytesNeoplasmsHumansMutationAnimalsAntigen PresentationAntigens, NeoplasmImmunotherapy

Substanzen

Tumor Suppressor Protein p53Antigens, Neoplasm

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: enewell@fredhutch.org.

Förderung

  • National Institutes of Health

Zitieren

APA

Newell, E. W. (2026). The narrow path to CD8+ T cell recognition of mutant p53. Immunity. https://doi.org/10.1016/j.immuni.2026.09.020

Vancouver

Newell EW. The narrow path to CD8+ T cell recognition of mutant p53. Immunity. 2026. doi:10.1016/j.immuni.2026.09.020

BibTeX
@article{Newell2026,
  author = {Newell, Evan W},
  title = {The narrow path to CD8+ T cell recognition of mutant p53},
  journal = {Immunity},
  year = {2026},
  doi = {10.1016/j.immuni.2026.09.020}
}
Kostenlos starten →